Thera-SAbDab

MIROMAVIMAB

>   Structural Summary
TherapeuticMiromavimab
TargetRabies Virus Strain ERA GP Ectodomain Epitope G-II
Heavy ChainQVQLQQPGSVLVRPGASVKLSCKTSGYAFTSSWMHWAKQRPGQGLEWIGQTHPNSGYTNYNEKFKGKATLTVDTSSSTAYVDLSSLTSEDSAVYYCARESGDGPHWYFDVWGAGTAVTVSS
Light ChainDIVMTQSHKFMSTSVGDRVSITCKASQDVSTAVAWYQQKPGQSPKLLIYSASYRYTGVPDRFTGSGSGTDFTFTISSVQAEDLAVYYCQQHYSSPHTFGGGTKLETK
100% seqID Fv StructureNone
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
FormatWhole mAb (Mouse)
IsotypeG1
Highest Clinical Trial (June '19)Unknown
Estimated Status (June '19)Active
Recorded Developmental Technologyna
INN Year Proposed2019
INN Year RecommendedNone
Companies InvolvedCandila Healthcare
Conditions Approvedna
Conditions ActiveRabies post-exposure
Conditions Discontinuedna
Notes

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]